Assignee
PACT PHARMA INC
US·7 granted patents·11 pending applications·9 citations·filing 2019–2023
Top patents by PatentIndex Score
18 records- 0192US10584357B2Primary cell gene editingPACT PHARMA INC·Filed 2019·Granted Mar 10, 2020·4 cites·7 claims
- 0288US11304978B2Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapyPACT PHARMA INC·Filed 2020·Granted Apr 19, 2022·2 cites·24 claims
- 0386US10550406B2Primary cell gene editingPACT PHARMA INC·Filed 2019·Granted Feb 4, 2020·1 cites·11 claims
- 0483US10676758B1Primary cell gene editingPACT PHARMA INC·Filed 2020·Granted Jun 9, 2020·1 cites·26 claims
- 0577US11513113B2Compositions and methods for identification of antigen specific T cellsPACT PHARMA INC·Filed 2020·Granted Nov 29, 2022·1 cites·16 claims
- 0677US2021395783A1Primary cell gene editingPACT PHARMA INC·Filed 2021·Application pending·0 cites
- 0772US10711283B2Primary cell gene editingPACT PHARMA INC·Filed 2020·Granted Jul 14, 2020·0 cites·25 claims
- 0872US2020299730A1Primary cell gene editingPACT PHARMA INC·Filed 2020·Application pending·0 cites
- 0968US10875905B2Peptide-MHC compactsPACT PHARMA INC·Filed 2019·Granted Dec 29, 2020·0 cites·18 claims
- 1066US2024016844A1Methods of treatment using a genetically modified autologous t cell immunotherapyPACT PHARMA INC·Filed 2023·Application pending·0 cites
- 1165US2021085720A1Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapyPACT PHARMA INC·Filed 2020·Application pending·0 cites
- 1260US2024066063A1COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPYPACT PHARMA INC·Filed 2023·Application pending·0 cites
- 1359US2023355762A1Compositions and methods for the treatment of cancer using next generation engineered t cell therapyPACT PHARMA INC·Filed 2023·Application pending·0 cites
- 1458US2023136076A1Methods of determining gene editing eficiencies in cellsPACT PHARMA INC·Filed 2022·Application pending·0 cites
- 1555US2021205363A1Methods of treatment using a genetically modified autologous t cell immunotherapyPACT PHARMA INC·Filed 2020·Application pending·0 cites
- 1653US2021230544A1Antigen specific tcr identification using single-cell sortingPACT PHARMA INC·Filed 2021·Application pending·0 cites
- 1752US2022010274A1Personalized neoantigen-specific adoptive cell therapiesPACT PHARMA INC·Filed 2021·Application pending·0 cites
- 1849US2021106621A1Method of treating immunotherapy non-responders with an autologous cell therapyPACT PHARMA INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PACT PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →